Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT516 in r/r AML and B-Cell Lymphoma
NCT04023071Phase 1Terminated
- Sponsor
- Fate Therapeutics
- Start
- Oct 2019
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of ft516 in acute myeloid leukemia (AML) and B cell lymphoma (4 arms), sponsored by Fate Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicities at Day 29 and Incidence, nature, and severity of Adverse Events up to 5 years. Started Oct 2019; status: terminated.
02
Drugs
ft516
03
Conditions
acute myeloid leukemia (AML)B cell lymphoma
Beyond the preview
Go deeper on NCT04023071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023071.